Lymphoma

First-Line Chemoimmunotherapy Outcomes in Primary Mediastinal B-Cell Lymphoma

By

Researchers sought to determine the results of first-line treatment of patients with primary mediastinal B-cell lymphoma.

This fact sheet provides an overview of the updated ESMO clinical practice guideline for hereditary GI cancers.

Ibrutinib May Reduce Risk of Bleeding Events in Acquired von Willebrand Syndrome Secondary to Waldenström Macroglobulinemia

By

Jonathan Goodman, MPhil

Researchers described a case study that suggested ibrutinib may have beneficial effects in patients with acquired von Willebrand syndrome that is secondary to Waldenström macroglobulinemia.

Shorter Obinutuzumab Infusions May Be Safe, Effective in Follicular Lymphoma

By

Jonathan Goodman, MPhil

Researchers sought for approval in Europe for obinutuzumab to be administered for a shorter, 90-minute infusion time among patients with previously untreated or previously treated follicular lymphoma.

Zanubrutinib Shows Promising Response Rate in Relapsed, Refractory Marginal Zone Lymphoma

By

Jonathan Goodman, MPhil

Researchers sought to determine whether zanubrutinib would have a positive response in patients with relapsed/refractory marginal zone lymphoma.

MRD Assessment Can Guide Treatment Discontinuation in CLL/SLL

By

Sucharita Mistry, PhD

Stopping treatment after induction did not impact disease-free survival in patients with undetectable minimal residual disease.

Macrophage Counts in Tumor Microenvironment May Predict Prognosis for Mantle Cell Lymphoma

By

Patricia Chaney

Researchers sought to determine whether lymphoma-associated macrophage counts could affect the prognosis of patients with MCL.

Brentuximab Vedotin Provides ‘Robust Clinical Benefit’ in Cutaneous T-Cell Lymphoma

By

Sucharita Mistry, PhD

Time to next treatment was significantly longer with brentuximab vedotin.

Effect of Bundle Nursing on Thrombosis Risk in Patients With Non-Hodgkin Lymphoma

By

Jessica Nye, PhD

A single-institution study determined the effect of a novel nursing practice on incidence of PICC-UEDVT, outcomes, and satisfaction with care in patients with NHL.

Autologous HSCT Provides Long-Term Survival Benefit in Mantle Cell Lymphoma

By

Sucharita Mistry, PhD

Transplant improved progression-free and overall survival at a median follow-up of 14 years.

Distance to treatment facilities can affect treatment choice.

Patient Willingness to Travel for DLBCL Care Varies by Race, Other Factors

By

Vicki Moore, PhD

Patients with DLBCL may be willing to travel longer distances for treatment if follow-up care was local, but this pattern varied by race.

Doctor talking to patient in hospital bed.

Polatuzumab Vedotin May Be Effective Salvage or Bridging Therapy for Large B-Cell Lymphomas

By

Patricia Chaney

Researchers sought to determine whether polatuzumab vedotin may be effective salvage or bridging treatment to CAR-T therapy for patients with relapsed/refractory LBCL.

Woman preparing COVID-19 vaccine injection.

Patients With B-Cell Non-Hodgkin Lymphoma Treated With Anti-CD20 Antibodies Have Impaired Response to COVID-19 Vaccine

By

Patricia Chaney

Researchers sought to determine whether patients with B-NHL who had treatment with anti-CD20 antibodies had an impaired serological response to an mRNA COVID-19 vaccine.

Inflammatory Biomarkers Help Predict Toxicity With CAR-T Cell Therapy

By

Patricia Chaney

Researchers sought to determine whether measures of inflammation would be associated with immune-related toxicities after CAR-T therapy.

Brentuximab Vedotin, Nivolumab Combination Shows Promise in Relapsed/Refractory Hodgkin Lymphoma

By

Jonathan Goodman, MPhil

Researchers sought to determine whether combining brentuximab vedotin with nivolumab would have positive PFS in patients with cHL.

Lenalidomide Not Effective for Central Nervous System Relapse Prevention in Patients With Diffuse Large B-Cell Lymphoma

By

Patricia Chaney

Researchers sought to determine if treatment with lenalidomide could prevent CNS relapses in patients with DLBCL.

Combination Antiretroviral Therapy and CD4/CD8 Ratio on the Risk for Kaposi Sarcoma, Non-Hodgkin Lymphoma in Patients With HIV Infection

By

Sweta Gupta

Researchers sough to assess the relationship between CD4/CD8 ratios and the risk for Kaposi sarcoma and non-Hodgkin lymphoma among patients with HIV infection treated with combination antiretroviral therapy.

Over half of evaluable patients who received an infusion of tisagenlecleucel achieved response.

Brukinsa Gets Accelerated Approval for Marginal Zone Lymphoma

By

Brian Park, PharmD

The approval was based on data from 2 single-arm clinical trials in adults with relapsed or refractory marginal zone lymphoma who have received at least 1 anti-CD20-based regimen.

Combination Temsirolimus and Lenalidomide Seems Feasible in Relapsed/Refractory Lymphomas

By

Lauren Dembeck, PhD

Researchers sought to determine whether combination therapy with temsirolimus and lenalidomide would have therapeutic activity in patients with heavily pretreated lymphomas.

Rituximab Biosimilars Produce Comparable Outcomes in Diffuse Large B-Cell Lymphoma

By

Leah Lawrence

Response and survival outcomes were similar with rituximab biosimilars and the originator.

CT-P10 and GP2013 exhibit non-inferior overall response efficacy and equivalent pharmacokinetics to

Nivolumab Rechallenge May Benefit Patients With Relapsed, Refractory Hodgkin Lymphoma

By

Jonathan Goodman, MPhil

Researchers sought to determine whether patients with relapsed or refractory classical Hodgkin lymphoma can receive benefit when retreated with nivolumab.

Patients With Lymphoma May Develop Antibodies for COVID-19 Vaccine 6 Months After Treatment

By

Patricia Chaney

Researchers sought to determine whether patients with lymphoma would develop antibodies with a COVID-19 vaccine 6 months after treatment with anti-CD20-containing therapy.

Bone Marrow and Extracellular Vesicles Associated With Development of Follicular Lymphoma B Cells

By

Vicki Moore, PhD

Researchers sought to determine whether there is a role for extracellular vesicles associated with follicular lymphoma B cells in the alteration of bone marrow stroma.

A family discusses fertility options with a clinician.

Treatment Impacts on Fertility for Patients With Hodgkin Lymphoma or Diffuse Large B-Cell Lymphoma

By

Vicki Moore, PhD

Researchers sought to determine the fertility-related issues and approaches for survivors of Hodgkin lymphoma and diffuse large B-cell lymphoma.

A nurse reviews a treatment plan with her patient.

Baseline SUVmax May Have Prognostic Value in Patients With Follicular Lymphoma

By

Jonathan Goodman, MPhil

Researchers sought to determine whether baseline SUVmax would have prognostic value in patients with follicular lymphoma.

Targeted and immunotherapies appear to be opening a new frontier in the management of elderly patien

Older Patients With NHL at High Risk for Treatment-Related Toxicity Events

By

Jessica Nye, PhD

A retrospective study revealed age-based risks for toxicities in patients with NHL treated with high-dose chemotherapy and autologous hematopoietic cell transplantation.

Diffuse B-Cell Lymphoma of CNS After Dimethyl Fumarate Treatment in RRMS

By

Brandon May

This case study showed that B-cell type primary central nervous system lymphoma may rapidly progress following dimethyl fumarate treatment in patients with relapsing remitting MS.

Circulating Tumor DNA May Predict Outcomes of CAR T-Cell Therapy in Large B-Cell Lymphoma

By

Sucharita Mistry, PhD

Circulating tumor DNA may identify patients at risk of relapse after axicabtagene ciloleucel.

A patient with cancer waits for treatment.

Intratumoral T-Cells Affect FDG-PET Prognostic Efficacy in Follicular Lymphoma

By

Patricia Chaney

Researchers sought to determine how chemoimmunotherapies can affect FDG-PET parameters and influence interpretation of results in patients with FL.

In addition to current obinutuzumab- and rituximab-based treatment regimens, several novel agents have received approval for follicular lymphoma treatment.

Primary Central Nervous System Lymphoma May Be Treated by Methotrexate Outside Clinical Trials

By

Patricia Chaney

Researchers sought to determine whether patients with PCNSL who are not eligible for clinical trials may benefit from high-dose methotrexate.

Brentuximab Vedotin May Improve Outcomes in Anaplastic Large Cell Lymphoma

By

Jonathan Goodman, MPhil

Researchers sought to determine whether adding brentuximab vedotin to chemotherapy would be safe and effective in pediatric patients with ALCL.

Patients who received autologous transplant followed by allogeneic transplant experienced improved progression-free survival.

Low-Cost Transcript-Based Method Developed for Diagnosing Lymphoma Biopsy Samples

By

Vicki Moore, PhD

Researchers sought to develop a low-cost, machine learning-based approach to diagnosing paraffin-embedded lymphoma biopsy specimens.

Diagnostic Features of Nodular Lymphocyte-Predominant Hodgkin Lymphoma

By

Vicki Moore, PhD

In a review, researchers explained diagnostic features associated with the rare condition of nodular lymphocyte-predominant Hodgkin lymphoma.

HDMTX Promising for Patients With Primary CNS Lymphoma Ineligible for Clinical Trials

By

Jennifer Larson

Researchers compared outcomes in patients with PCNSL who did not meet clinical trial criteria with those of patients from a major multicenter clinical trial of PCNSL.

A doctor explains a medication to an older patient.

LRPAP1 Autoantibodies Have Prognostic Value in Mantle Cell Lymphoma

By

Patricia Chaney

Researchers sought to determine whether the presence of LRPAP1 autoantibodies may predict clinical outcomes in patients with MCL.

Increasing genetic complexity over time allows multiple myeloma to acquire drug resistance, but immu

Gene Expression Shows New Mechanism of Action With Chidamide Therapy in Peripheral T-Cell Lymphoma

By

Vicki Moore, PhD

Researchers sought to identify a new possible immune-related mechanism of action associated with chidamide for treatment of patients with PTCL.

If a patient develops any adverse event while on ponatinib, clinicians should perform a risk-benefit

Zanubrutinib Yields Durable Responses in Patients With Relapsed/Refractory Mantle Cell Lymphoma

By

Lauren Dembeck, PhD

Researchers sought to determine whether zanubrutinib would have a high response rate and extended progression-free survival in patients with R/R mantle cell lymphoma.

Novel Model Shows High Predictive Potential in Patients With DLBCL

By

Jonathan Goodman, MPhil

Researchers sought to determine whether a novel model that combines signatures of metabolic dysregulation with clinical features may aid in clinical decision-making among patients with DLBCL.

More than 75% of patients achieved complete response after 1 cycle of the chemotherapy regimen.

Fixed-Duration Chemo-Free Treatment Efficacious in Patients With Relapsed/Refractory Waldenström Macroglobulinemia

By

Lauren Dembeck, PhD

Researchers sought to determine whether fixed-duration chemotherapy-free treatment with obinutuzumab and idelalisib would be effective in patients with R/R WM.

Recommended Dose Determined for Loncastuximab Tesirine in B-Cell Non-Hodgkin Lymphoma

By

Patricia Chaney

Researchers sought to determine the maximum and recommended phase 2 dose for loncastuximab tesirine in patients with B-cell NHL.

Photomicrograph showing mantle cell lymphoma / Science Source

SYMPATICO Trial: Ibrutinib Plus Venetoclax in Patients With Mantle Cell Lymphoma

By

Cancer Therapy Advisor Staff

Researchers are seeking to compare the efficacy and safety of the combination of ibrutinib and venetoclax compared with ibrutinib and placebo in patients with mantle cell lymphoma.

Survival Rates for Allogeneic, Autologous HSCT Are Similar in Patients With R/R Peripheral T-Cell Lymphoma

By

Jessica Nye, PhD

Researchers sought to determine which hematopoietic stem cell transplantation procedure is more efficacious for patients with refractory/relapsed peripheral T-cell lymphoma.

Cognition, Functioning Deficits in Survivors of Pediatric Extracranial Solid Tumors and Lymphomas

By

Bette Weinstein Kaplan

A review of the literature identified common deficits in cognitive functioning experienced by survivors of pediatric cancers.

Mogamulizumab Offers Glimmer of Hope for Relapsed T-cell Lymphomas

Potential Prognostic Marker for Extranodal Natural Killer T-Cell Lymphoma

By

Vicki Moore, PhD

Researchers sought to identify possible prognostic markers in extranodal natural killer T-cell lymphoma through an analysis of gene expression profiling data.

Chemotherapy Followed by Autologous Stem Cell Transplantation Shows Promise as First-Line Treatment for T-Cell Non-Hodgkin Lymphoma

By

Patricia Chaney

Researchers sought to determine whether first-line chemotherapy followed by high-dose therapy and auto-SCT would be the preferred treatment for patients under 60 with T-NHL.